RHOPHYLAC®

Human Anti-D immunoglobulin, solution for injection in a pre-filled syringe

RHOPHYLAC®, manufactured by CSL Behring, will be distributed from early July 2011 as the Rh(D) immunoglobulin for intravenous use available within Australia.

RHOPHYLAC® is supplied for use in large fetomaternal haemorrhage (FMH), or for inadvertent or emergency transfusion of Rh (D) positive blood to an Rh (D) negative female of childbearing potential. 

The introduction of RHOPHYLAC® will not affect the current Guidelines for the Prophylactic Use of Rh (D) Immunoglobulin (Anti-D) in Obstetrics. 

Healthcare professionals should order RHOPHYLAC® from the Australian Red Cross Blood Service.


Who is this information for?
This information is relevant in Australia and is intended for healthcare professionals.


Consumer Medicine Information
The Consumer Medicine Information is a leaflet written for people who have been prescribed Rh(D) Immunoglobulin-VF and contains information about the medicine including:
  • What RHOPHYLAC® is used for
  • How RHOPHYLAC® works
  • How RHOPHYLAC® is given
  • Side effects
  • Further Information

PDF icon RHOPHYLAC Consumer Medicine Information (PDF, 0.04 MB)


Product Information
Product Information contains information to ensure the safe and effective use of a medicine. This document is approved by the Therapeutic Goods Administration and made available by CSL for you if you are a qualified healthcare professional.

RHOPHYLAC® Product Information (PDF, 0.08MB)

® Registered Trademark of CSL Limited Group of Companies

Last Updated: 03/06/2015
© 2016 CSL Limited